神经母细胞瘤治疗中分化调节剂和靶向药物的研发。
Development of differentiation modulators and targeted agents for treating neuroblastoma.
机构信息
Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
出版信息
Eur J Med Chem. 2020 Dec 1;207:112818. doi: 10.1016/j.ejmech.2020.112818. Epub 2020 Sep 8.
Neuroblastoma (NB) is one of the most common pediatric malignancies. Easy metastasis, poor prognosis, and a high degree of heterogeneity of NB hinder its successful treatment. Several different therapeutic strategies have been developed to overcome these problems, including differentiation and targeted therapy. In this review, we summarize the recent development of differentiation modulators and targeted agents for treating NB. Several promising targets of NB were also discussed.
神经母细胞瘤（NB）是儿童最常见的恶性肿瘤之一。NB 易转移、预后差、异质性高，这些特点阻碍了其成功治疗。为了克服这些问题，已经开发了几种不同的治疗策略，包括分化治疗和靶向治疗。在这篇综述中，我们总结了用于治疗 NB 的分化调节剂和靶向药物的最新进展。还讨论了 NB 的一些有前途的靶点。
Zotero 插件